COVID-19 Vaccine Data Was Peer-Reviewed, Contrary to Meme’s Claim

All of the authorized vaccines are effective at preventing symptomatic disease.

According to the results of the phase 3 trials, the Pfizer/BioNTech and Moderna vaccines had an efficacy of 94% or higher, which means your approximate risk of getting sick is cut by 94% or more if you are vaccinated. It’s important to keep in mind that the effectiveness of the vaccines outside the controlled setting of a clinical trial is typically somewhat lower. A study by the Centers for Disease Control and Prevention found these two vaccines were 90% effective in real-world conditions, two weeks after the second dose, and 80% effective two weeks after the first dose. The study monitored 3,950 health care personnel, first responders and other essential workers for 13 weeks.   

Johnson & Johnson’s phase 3 trial began in , nearly two in South Africa. Globally, J&J an efficacy of 66.1% in preventing moderate to severe COVID-19 and an efficacy of 85.4% in preventing severe or critical COVID-19. But efficacy was higher in the U.S. population (72% efficacy in preventing moderate to severe disease and 85.9% efficacy in preventing severe or critical disease) than in South Africa (64% and 81.7% efficacy in preventing moderate to severe or severe/critical disease, respectively).